Japan links treatment of hepatitis C with reduced progression of liver cancer
Study has shown that removing hepatitis C virus with direct-acting antivirals suppresses tumor progression
In a new cohort study of patients with hepatocellular carcinoma (HCC) linked to hepatitis C virus (HCV), a disease with a high recurrence rate, researchers at the École supérieure de médecine de la Osaka University in Japan have reported that after receiving cancer treatment, oral administration of direct-acting antivirals (DAAs) reduces the risk of tumor progression following recurrence of liver disease.
“Although it is considered weak or inconclusive that treatment with DAA helps prevent recurrence of HCC, little is known about how antiviral treatment affects the progression of liver disease after cancer treatment. “the researchers said.
HCV infection affects 71 million people worldwide and accounts for about 65% of the causes of liver cancer in Japan. While the team will continue to investigate issues such as the extent to which cirrhosis and liver function improve after antiviral treatment, as supporting author and speaker Sawako Uchida-Kobayashi puts it, “the The suppressive effect of DAA treatment on cancer progression revealed by our study is hopefully improving the overall quality of life of people with HCC.